=Alexion Pharma (ALXN) reported earnings on Thur 27 July 2017 (b/o)

Alexion Pharma beats by $0.30, beats on revs; raises FY17 EPS above consensus :

• Reports Q2 (Jun) earnings of $1.56 per share, $0.30 better than the Capital IQ Consensus of $1.26; revenues rose 21.1% year/year to $912 mln vs the $846.15 mln Capital IQ Consensus.
• Co raises guidance for FY17, sees EPS of $5.40-5.55 vs. $5.33 Capital IQ Consensus Estimate, compared to $5.10-5.30 prior
• Co raises guidance for FY17 - sees revs of $3.45-3.53 bln vs. $3.47 bln Capital IQ Consensus Estimate, compared to $3.4-3.5 bln prior